INTEGRAL DIAGNOSTICS LIMITED (IDX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IDX - INTEGRAL DIAGNOSTICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 4.02
Index: ASX300 | ALL-ORDS

Integral Diagnostics is an Australian healthcare services company providing diagnostic imaging services to medical practitioners in Australia and New Zealand. It has been a listed company since 2015.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$3.02

07 Oct
2024

-0.030

OPEN

$3.05

-0.98%

HIGH

$3.05

128,561

LOW

$2.98

TARGET
$3.10 2.6% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
IDX: 1
Title FY23
Actual
FY24
Actual
FY25
Forecast
FY26
Forecast
EPS (cps) xxx - 26.0 11.3 xxx
DPS (cps) xxx 5.8 8.6 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx - 3.3% 47.4% xxx
PE Ratio xxx N/A 26.6 xxx
Dividend Yield xxx N/A 2.8% xxx
Div Pay Ratio(%) xxx N/A 75.7% xxx

Dividend yield today if purchased 3 years ago: 1.16%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

1.93

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 29/02 - ex-div 2.5c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-26.0
DPS All xxxxxxxxxxxxxxx5.8
Sales/Revenue xxxxxxxxxxxxxxx469.7 M
Book Value Per Share xxxxxxxxxxxxxxx129.0
Net Operating Cash Flow xxxxxxxxxxxxxxx66.2 M
Net Profit Margin xxxxxxxxxxxxxxx-12.92 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-17.99 %
Return on Invested Capital xxxxxxxxxxxxxxx-8.89 %
Return on Assets xxxxxxxxxxxxxxx-7.67 %
Return on Equity xxxxxxxxxxxxxxx-17.99 %
Return on Total Capital xxxxxxxxxxxxxxx6.00 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx28.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx16 M
Long Term Debt xxxxxxxxxxxxxxx342 M
Total Debt xxxxxxxxxxxxxxx358 M
Goodwill - Gross xxxxxxxxxxxxxxx373 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx42 M
Price To Book Value xxxxxxxxxxxxxxx2.07

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx23.9 M
Capex % of Sales xxxxxxxxxxxxxxx5.08 %
Cost of Goods Sold xxxxxxxxxxxxxxx366 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx62 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

28/08/2024

1

Outperform

$2.90

-3.97%

Macquarie's forecasts suggest double-digit EPS accretion for Integral Diagnostics over FY25/FY26 assuming cost synergies pertaining to the Capitol Health ((CAJ)) merger are realised.

After reviewing FY24 results, the broker highlights the EBITDA margin expanded to 19.5% (as expected) with ongoing expansion anticipated in FY25 as head-count reductions annualise.

The target rises to $2.90 from $2.85. Outperform.

FORECAST
Macquarie forecasts a full year FY25 dividend of 8.00 cents and EPS of 11.00 cents.
Macquarie forecasts a full year FY26 dividend of 10.00 cents and EPS of 13.80 cents.

EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

04/09/2024

2

Upgrade to Overweight from Neutral

$2.83

-6.29%

Integral Diagnostics reported FY24 underlying profit 1.5% ahead of Jarden. The company delivered on guidance, achieving
a material improvement in earnings margin in the second half.

With FY24 now a solid base for both Integral Diagnostics and Capitol Health ((CAJ)) to build on, the upside potential of a combined group would be attractive, the broker suggests.

Target rises to $2.83 from $2.59 and the broker upgrades its rating to Overweight from Neutral given the earnings profile and upside potential from the proposed Capitol Health merger.

FORECAST
Jarden forecasts a full year FY25 dividend of 6.70 cents and EPS of 10.20 cents.
Jarden forecasts a full year FY26 dividend of 6.80 cents and EPS of 14.80 cents.

Wilsons

xx/xx/xxxx

1

xxxxxxx xx xxxxxxxxxx xxxx xxxxxx xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

IDX STOCK CHART